Prostate Cancer Support Group - Richmond, Va


Meeting Dates - 3rd Thurs. each month - Time 7:00 PM - No July Meeting - The Dec. date will vary - Call for details - Peter C. Moon Phd. at 804-346-4407 between 7 - 11:00 PM - Location - Ridge Baptist Church, 1515 Eastridge Road Richmond, VA 23229

Vet

Rva Prostate Cancer Support Group

www.rvaprostatecancersupport.org
RVA

Articles Bipolar Androgen Therapy Page

In good faith, this website was created to furnish you with helpful information. Nevertheless, no one who contributes or posts information to this website makes any guarantee regarding the information provided. Any decisions that you make regarding your health should be made in consultation with a qualified healthcare provider.


Affiliated with Us-TOO International Prostate Cancer Education & Support Network
Home Us Too International Other Support Groups Facts and Stats Emerging Treatments Contact Us Videos Complementary
Alternative Treatment Sources		 Links Peter's Notes Flyer

*******************************************************************************************************
Articles on Bipolar Androgen Therapy Decision Making

Prostate Cancer
*******************************************************************************************************
BAT

Us Too warriors,
I think the below article is of interest to all .

Peter

Samuel Ray Denmeade, MD - Professor of Oncology and Urology
Johns Hopkins University School of Medicine - Baltimore, Maryland

What is Bipolar Androgen Therapy (BAT)?
*************
BAT consists of the administration of a high dose of androgen—also called testosterone—in an effort to control prostate cancer in men whose tumors are progressing on androgen deprivation therapy (ADT). This causes the levels of testosterone in the blood to alternate between the polar extremes of very high and very low during a treatment cycle (Figure).

Could you describe your research on BAT in men with castration-resistant disease?
*************
SD Our group has conducted 3 studies in this area. Our pilot study was sponsored by the One-in-Six Fund, which was started by a patient of mine to support prostate cancer research. The study, whose results appeared in Science Translational Medicine in 2015, was conducted in 14 men with castration-resistant prostate cancer (CRPC), who received a monthly testosterone injection (400 mg) and 2 weeks of daily etoposide (100 mg) while continuing to undergo ADT. After 3 cycles, the men whose prostate specific antigen (PSA) level had decreased continued to receive BAT. We found that BAT was well tolerated, with PSA declines and radiographic response seen in half the patients we treated. Treatment with antiandrogen therapies after BAT resulted in a decrease in PSA levels in all patients.
*************
To Read more on this subject:
Click on Our Link

Link: BAT
or Go To
https://www.hematologyandoncology.net/files/2018/06/ho0618Prostate-1.pdf

*******************************************************************************************************